Research programme: anticancer monoclonal antibodies - MedImmune/Georgetown University

Drug Profile

Research programme: anticancer monoclonal antibodies - MedImmune/Georgetown University

Alternative Names: Anti-ALK MAb; Anti-anaplastic lymphoma kinase monoclonal antibodies

Latest Information Update: 09 Jan 2014

Price : $50

At a glance

  • Originator Georgetown University; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 11 Jan 2008 Preclinical development is ongoing
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 26 Sep 2005 Preclinical trials in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top